Growth Metrics

Volitionrx (VNRX) Liabilities and Shareholders Equity (2018 - 2025)

Volitionrx filings provide 11 years of Liabilities and Shareholders Equity readings, the most recent being $6.9 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 26.58% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.6 million, a 43.98% decrease, with the full-year FY2025 number at $6.9 million, down 26.58% from a year prior.
  • Liabilities and Shareholders Equity hit $6.9 million in Q4 2025 for Volitionrx, up from $6.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $35.2 million in Q2 2021 to a low of $6.4 million in Q3 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $18.3 million (2022), compared with a mean of $19.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 52.78% in 2023 and later tumbled 66.37% in 2024.
  • Volitionrx's Liabilities and Shareholders Equity stood at $27.5 million in 2021, then plummeted by 33.45% to $18.3 million in 2022, then skyrocketed by 52.78% to $28.0 million in 2023, then plummeted by 66.37% to $9.4 million in 2024, then fell by 26.58% to $6.9 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $6.9 million (Q4 2025), $6.4 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.